Yahoo Finance • last year
BOSTON and LONDON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the presentation of p... Full story
Yahoo Finance • last year
BOSTON and LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Chief Scientific... Full story
Yahoo Finance • last year
MIAMI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of Day 2 of the 63rd Emerging Growth Conference on October 5th, 2023. The Emerging Growth Conference identif... Full story
Yahoo Finance • last year
MIAMI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 63rd Emerging Growth Conference on October 4th and 5th, 2023. The Emerging Growth Conference identifi... Full story
Yahoo Finance • last year
Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase 3 clinical trials in pediatric and adult HSCT-TMA and start PAS-nomacopan clinical trials in geographic atrophy (GA)Granted orphan... Full story
Yahoo Finance • last year
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company wil... Full story
Yahoo Finance • last year
Event on October 19, 2023 will feature Sonata Jodele, MD and Professor Rob Wynn BOSTON and LONDON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapi... Full story
Yahoo Finance • last year
NEW YORK and LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases today announced the company has rec... Full story
Yahoo Finance • last year
NEW YORK and LONDON, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases today announced the establishment of... Full story
Yahoo Finance • last year
NEW YORK and LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari will cha... Full story
Yahoo Finance • last year
Akari is on track for start of enrollment by the end of 2023 in the registrational Phase 3 study of nomacopan in pediatric HSCT-TMA Akari is moving forward into a Phase 3 double-blind placebo-controlled clinical trial of nomacopan in adult... Full story
Yahoo Finance • last year
Akari has completed evaluation of long-acting PAS-nomacopan candidates and selected a single drug candidate to move forward into clinical trials for treatment of geographic atrophy (GA)The company remains on track for an IND submission in... Full story
Yahoo Finance • last year
NEW YORK and LONDON, July 06, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the European M... Full story
Yahoo Finance • last year
NEW YORK and LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of... Full story
Yahoo Finance • 2 years ago
AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has... Full story
Yahoo Finance • 2 years ago
NEW YORK and LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company wil... Full story
Yahoo Finance • 2 years ago
Development of lead asset nomacopan, a novel dual-mechanism inhibitor of complement C5 and leukotriene B4 (LTB4), is focused on two priority pipeline programs with potential to transform the complement inhibition category, as well as stand... Full story
Yahoo Finance • 2 years ago
NEW YORK and LONDON, April 03, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the upcoming prese... Full story
Yahoo Finance • 2 years ago
Third generation drug substance manufacturing process increases the final yield of nomacopan by at least 5-fold, improving cost efficiencies in the continuing Phase 3 clinical trial of nomacopan in pediatric hematopoietic stem cell transpl... Full story
Yahoo Finance • 2 years ago
NEW YORK and LONDON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the late-breaker pr... Full story